Showing results (41-50 of 49) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 14, 2023
Prediction of Adjuvant Gemcitabine Sensitivity in Resectable Pancreatic Adenocarcinoma Using the GemPred RNA Signature: An Ancillary Study of the PRODIGE-24/CCTG PA6 Clinical TrialRémy Nicolle, Jean-Baptiste Bachet, Alexandre Harlé, et al.
The Lancet. Oncology|June 4, 2024
Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): a single-arm, multicentre phase 1b/2 studyJean-Luc Van Laethem, Ivan Borbath, Hans Prenen, et al.
Cancer Treatment Reviews|July 1, 2026
Antiangiogenic therapies in gastric cancer: future directions for 2026 and beyond: an UNICANCER gastrointestinal group (UCGI) perspectiveJudith Raimbourg, Meher Ben Abdelghani, Valerie Boige, et al.
Medrxiv : the Preprint Server for Health Sciences|July 3, 2026
Emergency integrative supportive care program for frail patients with advanced pancreatic cancer: A prospective GERCOR ARCAD studyBenoit Rousseau, Marc Hilmi, Antoine Falcoz, et al.
The Lancet. Neurology|October 8, 2019
An exoskeleton controlled by an epidural wireless brain-machine interface in a tetraplegic patient: a proof-of-concept demonstrationAlim Louis Benabid, Thomas Costecalde, Andrey Eliseyev, et al.
Cell Reports. Medicine|October 8, 2025
CD40 agonist mitazalimab with mFOLFIRINOX in untreated metastatic pancreatic cancer: Biomarkers associated with outcomes from OPTIMIZE-1Jean-Luc Van Laethem, Karen Geboes, Ivan Borbath, et al.
European Journal of Cancer (Oxford, England : 1990)|March 8, 2022
Impact of the COVID-19 pandemic on disease stage and treatment for patients with pancreatic adenocarcinoma: A French comprehensive multicentre ambispective observational cohort study (CAPANCOVID)Mathias Brugel, Léa Letrillart, Camille Evrard, et al.
International Journal of Cancer|July 14, 2022
FOLFIRI plus BEvacizumab or aFLIbercept after FOLFOX-bevacizumab failure for COlorectal cancer (BEFLICO): An AGEO multicenter studyCécile Torregrosa, Simon Pernot, Pauline Vaflard, et al.
Nature Cancer|June 30, 2025
Efficacy of pembrolizumab and vorinostat combination in patients with recurrent and/or metastatic squamous cell carcinomas: a phase 2 basket trialEdith Borcoman, Bastien Cabarrou, Miguel Francisco, et al.
Pageof 5